Fig. 1. Effects of VEGF-A₁₆₄ antibody (ab, 5 μg) injected subcutaneously on CFA-induced thermal hyperalgesia. Subcutaneous injection of VEGF-A₁₆₄ antibody did not affect head withdrawal latency time in CFA-treated rats. There were six animals in each group.

Oral Biol Res 2023;47:151~158 https://doi.org/10.21851/obr.47.04.202312.151

© Oral Biol Res